MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10620-026-10188-1

Медицинская библиотека · Digestive diseases and sciences · 2026

Higher Off-Therapy Relapse Risk with Tenofovir Alafenamide than Entecavir in Non-cirrhotic HBeAg-Negative Chronic Hepatitis B: Insights from End-of-Treatment qHBsAg Stratification.

Huang Yi-Jie, Chang Chung-Hsin, Lee Shou-Wu, Tung Chun-Fang, Liao Szu-Chia, Lee Teng-Yu, Peng Yen-Chun, Wang Jun-Sing

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND AND AIMS: End-of-treatment (EOT) qHBsAg predicts off-therapy relapse in HBeAg-negative chronic hepatitis B (CHB), but whether its stratifying ability differs between entecavir (ETV) and tenofovir alafenamide (TAF) remains unclear. This study compared 12-month relapse risk across EOT qHBsAg strata after ETV or TAF discontinuation in non-cirrhotic HBeAg-negative CHB patients.

METHODS

In this retrospective cohort study, non-cirrhotic HBeAg-negative CHB patients discontinuing ETV or TAF were 1:1 propensity score matched. Virological relapse was assessed by Kaplan-Meier analysis and Cox regression; clinical relapse by cumulative incidence functions with Fine-Gray competing risks regression. Hazard ratios and subdistribution hazard ratios (sHRs) were compared across EOT qHBsAg strata (< 2, 2-3, ≥3 log10 IU/mL).

RESULTS

A total of 130 patients (65 per group) were analyzed. Among ETV discontinuers, clinical relapse rates increased progressively with higher EOT qHBsAg (0.0%, 14.6%, and 25.0% for <2, 2-3, and ≥3 log10 IU/mL, respectively). In contrast, TAF discontinuers showed persistently high virological (68.8%-86.3%) and clinical relapse rates (48.5%-57.1%) regardless of EOT qHBsAg level. The relapse risk difference was most pronounced at lower EOT qHBsAg: the sHR for clinical relapse (TAF vs. ETV) reached 5.164 (95% CI 2.131-12.515) at 2-3 log10 IU/mL, with no ETV events at <2 log10 IU/mL. Overall sHR was 5.633 (95% CI 2.801-11.329; p < 0.001).

CONCLUSIONS

EOT qHBsAg effectively stratifies clinical relapse risk after ETV discontinuation but shows limited discriminative ability after TAF cessation, where relapse rates remain uniformly high across all qHBsAg levels.

Для цитирования: Huang Yi-Jie, Chang Chung-Hsin, Lee Shou-Wu, Tung Chun-Fang, Liao Szu-Chia, Lee Teng-Yu, Peng Yen-Chun, Wang Jun-Sing. Higher Off-Therapy Relapse Risk with Tenofovir Alafenamide than Entecavir in Non-cirrhotic HBeAg-Negative Chronic Hepatitis B: Insights from End-of-Treatment qHBsAg Stratification.. Digestive diseases and sciences. 2026. DOI: 10.1007/s10620-026-10188-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.